Argá Medtech closes oversubscribed Series B funding for pulsed field ablation tech

Argá Medtech today announced it closed a €54 million oversubscribed Series B funding round to support its pulsed field ablation technology.

The Lausanne, Switzerland-based company develops the Coherent Sine-Burst Electroporation pulsed field ablation system for treating cardiac arrhythmias, including atrial fibrillation. Argá’s latest financing will allow the company to advance the development of its CSE system through an investigational device exemption study in the U.S. and a CE mark study in the EU. The company also plans to expand its U.S. offices in San Diego in anticipation of its clinical activities in the U.S.

The funding round was led by the existing investors, Advent Life Sciences and Earlybird Health, and new investor Gilde Healthcare and an undisclosed strategic investor.

Argá Medtech’s CSE ablation system helps electrophysiologists treat any region in the heart safely and efficiently in a single, multi-configurable catheter while…

Read more
  • 0